Compare Cipher Mining Inc (CIFR) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cipher Mining Inc vs Sanofi SA — how do they compare? Cipher Mining Inc trades at $17.94 (market cap $7.14B), while Sanofi SA trades at $44.08 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 14.6× Cipher Mining Inc's market cap, and Sanofi SA pays a 5.55% dividend while Cipher Mining Inc pays none. Which is the better fit depends on your goals.
| CIFR | SNY | |
|---|---|---|
Market Cap | $7.14B | $104.30B |
Sector | Basic Materials | Health |
52-Week High | $29.18 | $52.34 |
52-Week Low | $4.72 | $41.33 |
Enterprise Value | $11.90B | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CIFR trades at $17.87, up 9.43% in 24 hours, but remains in a bearish technical trend with significant fundamental challenges. The company reported a Q2 2026 loss of $0.65 per share, missing estimates, with revenue of $191 million and a net loss of $1.1 billion. Despite negative profitability metrics, analyst consensus is unanimously bullish with a $31.78 price target, citing progress in transitioning from Bitcoin mining to AI data center operations.
The outlook hinges on successful execution of its AI infrastructure pivot, but high valuation ratios and persistent losses pose substantial risks. Near-term support lies at $16, while resistance is at $18. Investor sentiment is divided between optimism over AI contracts and concerns over cash burn and mining dependency.
SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.
The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cipher Mining Inc
Cipher Mining is an industrial-scale technology company focused on Bitcoin mining infrastructure. It develops and operates data centers in the US designed to strengthen the Bitcoin network and support decentralized finance.
Read more on CIFR →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
